PriceTargets.com logo

ARS Pharmaceuticals - SPRY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $28.25
  • Forecasted Upside: 212.85%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$9.03 As of 05/5/2026 05:00 PM ET
▲ +0.2 (2.27%)

This chart shows the closing price for SPRY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ARS Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPRY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPRY

Analyst Price Target is $28.25
▲ +212.85% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ARS Pharmaceuticals in the last 3 months. The average price target is $28.25, with a high forecast of $32.00 and a low forecast of $25.00. The average price target represents a 212.85% upside from the last price of $9.03.

This chart shows the closing price for SPRY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in ARS Pharmaceuticals. This rating has held steady since January 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/11/2024
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/9/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/10/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/8/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
11/6/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
2/4/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/5/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/5/2026

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/24/2026Weiss RatingsDowngradeSell (D) ➝ Sell (D-)
4/9/2026Northland SecuritiesInitiated CoverageOutperform$25.00
3/10/2026Leerink PartnersSet TargetOutperform ➝ Outperform$26.00
2/25/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
1/27/2026Zacks ResearchDowngradeHold ➝ Strong Sell
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/20/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
11/4/2025Roth MkmInitiated CoverageBuy$30.00
10/22/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/26/2025Raymond James FinancialSet Target$32.00
9/4/2025Roth MkmInitiated CoverageBuy$40.00
3/7/2025ScotiabankInitiated CoverageSector Outperform$30.00
3/3/2025William BlairReiterated RatingOutperform
2/21/2025William BlairReiterated RatingOutperform
2/10/2025OppenheimerInitiated CoverageOutperform$40.00
1/14/2025Raymond James FinancialBoost TargetStrong-Buy ➝ Strong-Buy$26.00 ➝ $28.00
1/13/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$26.00 ➝ $27.00
10/8/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
9/20/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$21.00 ➝ $25.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
8/30/2024William BlairUpgradeStrong-Buy
8/20/2024Cantor FitzgeraldInitiated CoverageOverweight$30.00
8/13/2024Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$18.00 ➝ $22.00
8/12/2024Leerink PartnersBoost TargetOutperform$19.00 ➝ $20.00
7/25/2024Raymond James FinancialInitiated CoverageOutperform$18.00
3/11/2024WedbushReiterated RatingOutperform$19.00
3/5/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$6.00 ➝ $18.00
2/21/2024WedbushReiterated RatingOutperform$19.00
2/20/2024William BlairUpgradeMarket Perform ➝ Outperform
11/13/2023WedbushBoost TargetOutperform ➝ Outperform$5.00 ➝ $13.00
9/21/2023WedbushLower TargetOutperform ➝ Outperform$15.00 ➝ $5.00
9/21/2023Leerink PartnersDowngradeOutperform ➝ Market Perform
9/20/2023William BlairDowngradeOutperform ➝ Market Perform
8/14/2023WedbushReiterated RatingOutperform ➝ Outperform$15.00
1/31/2023WedbushInitiated CoverageOutperform$10.00
1/3/2023William BlairInitiated CoverageOutperform$17.00
12/13/2022Leerink PartnersInitiated CoverageOutperform$14.00
(Data available from 5/6/2021 forward)

News Sentiment Rating

1.21 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/7/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/6/2025
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/6/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/5/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/4/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/6/2026
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/5/2026
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/5/2026

Current Sentiment

  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ARS Pharmaceuticals logo
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $9.03
Low: $8.85
High: $9.13

50 Day Range

MA: $8.41
Low: $7.54
High: $9.34

52 Week Range

Now: $9.03
Low: $6.66
High: $18.90

Volume

1,525,435 shs

Average Volume

1,592,386 shs

Market Capitalization

$896.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of ARS Pharmaceuticals?

The following equities research analysts have issued stock ratings on ARS Pharmaceuticals in the last twelve months: Leerink Partners, Northland Securities, Raymond James Financial, Inc., Roth Mkm, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for SPRY.

What is the current price target for ARS Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for ARS Pharmaceuticals in the last year. Their average twelve-month price target is $28.25, suggesting a possible upside of 212.8%. Raymond James Financial, Inc. has the highest price target set, predicting SPRY will reach $32.00 in the next twelve months. Northland Securities has the lowest price target set, forecasting a price of $25.00 for ARS Pharmaceuticals in the next year.
View the latest price targets for SPRY.

What is the current consensus analyst rating for ARS Pharmaceuticals?

ARS Pharmaceuticals currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SPRY, but not buy more shares or sell existing shares.
View the latest ratings for SPRY.

What other companies compete with ARS Pharmaceuticals?

Other companies that are similar to ARS Pharmaceuticals include Edgewise Therapeutics, NewAmsterdam Pharma, Arcus Biosciences, Alumis and Beam Therapeutics. Learn More about companies similar to ARS Pharmaceuticals.

How do I contact ARS Pharmaceuticals' investor relations team?

ARS Pharmaceuticals' physical mailing address is 500 Fairview Ave N Suite 600, Seattle WA, 98109. The company's listed phone number is 206-456-2900 and its investor relations email address is [email protected]. The official website for ARS Pharmaceuticals is ars-pharma.com. Learn More about contacing ARS Pharmaceuticals investor relations.